In a pivotal phase III clinical trial investigating first-line immunotherapy combined with chemotherapy for extensive-stage SCLC, the KRAS mutation status was neither reported nor assessed for its impact on therapeutic efficacy. Here, KRAS is linked to small cell lung carcinoma.